Deliver Your News to the World

Gilboa Therapeutics Publishes and Presents Data at AACR Supporting SolidT Engineered T-Cell Platform Targeting Solid Tumors

Gilboa will present in vitro and in vivo data at the AACR Annual Meeting demonstrating non-clinical proof of concept for SolidT cells coadministered with therapeutic antibodies

Cambridge, MA – WEBWIRE

Gilboa Therapeutics, a preclinical stage biotechnology company, today announced the publication of a scientific paper demonstrating that its novel T-cell therapy platform, SolidT, has the potential to reprogram T cells to detect and destroy solid tumor cells while leaving normal cells unharmed. The paper was published in Cancer Immunology Research, a journal of the American Association for Cancer Research (AACR).

The company will be presenting its data in a poster at the AACR Annual Meeting on April 18 at 9AM ET in Section 22.

Until now, treatment of solid tumors with autologous T-cell therapies, such as CAR-T, have been limited by T-cell exhaustion, toxicity, and immunosuppressive tumor microenvironments. Furthermore, each solid tumor target requires a unique CAR-T cell product. Gilboa’s SolidT technology overcomes these limitations by utilizing a novel, engineered antibody receptor whereby the SolidT cells are activated specifically against high antigen expressing tumor cells, while sparing normal cells with low expression of the same antigens. The SolidT cells are engineered to target tumor cells via coadministration with therapeutic monoclonal antibodies. This activation mechanism prevents premature exhaustion, while also reducing the risk of systemic cytokine-related toxicities. It also allows for a single manufacturing process to generate SolidT cells to be used across multiple tumor types.

“We’re confident this new T-cell therapy has the potential to become a highly flexible and effective treatment for solid tumors,” stated Barry Labinger, CEO of Gilboa Therapeutics. “We’re excited to continue our work to bring this potentially life-saving therapy first to clinical trials and ultimately to patients around the world.”

Gilboa is developing its proprietary SolidT technology, which originated in Dr. Yaron Carmi’s lab at Tel Aviv University. SolidT therapy is based on T cells that are genetically engineered to express a modified, high-affinity antibody receptor. This antibody receptor allows the engineered T cells to target antibody-coated tumor cells. SolidT cells are designed to deliver a highly specific and potent attack that has been highly active against a variety of tumors in challenging animal models, while leaving healthy tissues unharmed. SolidT is an innovative platform technology that has the potential to benefit patients with a range of both solid and hematological tumors, with an improved safety profile compared to other cell therapy approaches.

The full paper can be viewed at:

About Gilboa Therapeutics​

Gilboa Therapeutics is a preclinical-stage biopharmaceutical company that is focused on the development of novel and high-impact, next-generation cancer immunotherapies designed to harness the power of patients’ own immune systems to treat cancer, improve outcomes and save lives. Backed by NFX, company’s SolidT technology leverages T-cells that are genetically engineered to target tumor cells while leaving healthy tissue unharmed. Learn more at

( Press Release Image: )


 Gilboa Therapeutics
 Solid Tumor
 T-cell Therapy

This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.